Case Processing Services

Case Processing Services

  • High number of ICSRs received daily from different sources WW (10,000+ ICSRs / year)
  • Challenging internal timelines for PV activities
  • Limited resources in the client affiliates.
  • High volume of SOPs and Working Practices to follow daily
  • Harmonization of processes in all local affiliates: China, Italy, Brazil, Venezuela, UK, The Netherlands, Peru, Belgium, Australia, Romania, Canada and US

Posted:

Download

Support with retrieval of ICSR Follow-Up information

Support with retrieval of ICSR Follow-Up information

  • ICSR processing carried out within the client organization following client’s procedural documents
  • Need to outsource retrieval of follow-Up information as one single part of ICSR processing due to limited resources
  • Wish to streamline the process with only one preferred service provider
  • Integration of PharmaLex personnel into given processes and procedural documents

Posted:

Download

Global PV Outsourcing

Global PV Outsourcing

  • Globally operating pharma company requested support concerning quality management and operative PV activities with the focus on case processing
  • Client was thus looking for one preferred service provider with an international company structure
  • Responsibilities included all workflows and activities relevant for case processing and quality management

Posted:

Download

Full PV Outsourcing of a Global Generics Pharma Company

Full PV Outsourcing of a Global Generics Pharma Company

  • The company was new founded and took over a significant number of products from another MAHs woman’s health portfolio
  • No PV system or other PV related structures where in place
  • Local structures needed to be established in 45 countries
  • PharmaLex offers:
    • Set up of a completely new pharmacovigilance (PV) system including QPPV, LPPVs, PSMF, PV SOP updates, and data migration to new safety database
    • Maintenance of the PV System after marketing authorizations were transferred to the new MAH

Posted:

Download

Safety Detection and Signal Management

Efficient End to End Pharmacovigilance services according to GVP

  • The marketing authorisation holder in the EU should continuously monitor the safety of their medicinal products and inform the authorities of any new information that might have an impact on the marketing authorisation [DIR Art 23(2), REG Art 16(2)](GVP Module IX)
  • Client was rapidly increasing portfolio with M&A with over 1500 marketing authorizations with complex partner network systems
  • Implement a process for integrating the activities performed by PharmaLex into the client’s system

Posted:

Download

Drug Product Release Specification Justification

Client lacks knowledge of critical quality standards for drug product release

  • Specifications are critical quality standards that are crucial for approval when submitted to the authorities

Posted:

Download

Data Science long-term support to a global submission dossier

Needed to perform multiple calibration studies for IVD

  • Statistical and pharmacokinetic input in each application dossier (e.g. modules 2.7.2 and 5 for FDA)
  • Need to summarize heterogeneous information from different sources and providers used during the clinical development
  • Quick feedback including new analyses to support the answers to the questions raised by the different regulatory agencies

Posted:

Download

Tolerance intervals solution

Reluctance to compute tolerance intervals

  • Scientists in the pharma industry are reluctant to compute tolerance intervals and therefore cannot assess the control limits for each analytical method and process rapidly

Posted:

Download

Setting calibration frequency for an IVD

Needed to perform multiple calibration studies for IVD

  • A client selling In VitroDiagnostics (IVD) tools had to perform laborious studies to establish the frequency of calibration to be applied on their IVD tools
  • Knowing that the required calibration frequency is directly linked to the stability of the reagents used, why not use stability data to predict a calibration frequency that still guarantees performance of the assay?

Posted:

Download

System suitability control limits for assay with format

Client lacked sufficient knowledge of System Suitability Control (SSC)

  • For assays, scientists develop SSC, to mitigate large assay variability with biologics and vaccine, samples are frequently analyzed in replication over multiple runs, and the mean of all the results is taken as reportable value
  • Variability analysis of these replicates could lead to the detection of assay problem (sample preparation, etc.) but specifications for simultaneous, replicate determinations do not exist to obtain an easy pass / fail decision process

Posted:

Download

Preparing for process characterization activities

Support required for process characterization activities

  • The client has produced several batches of product and wishes to use the different results from the manufacturing campaign to start process characterization activities
  • A large dataset is provided containing information on process parameters and material attributes across the process
  • Client project was blocked due to lack of internal process characterization capabilities

Posted:

Download

Post-regulatory support to an EMA clinical submission

Support required to respond to EMA feedback on study results

  • Several concerns raised by EMA on the design of the pivotal study for the registration of a generic drug diffusion system (DDS)

Posted:

Download

Setup an Atlassian product (Jira, confluence)

Client wants to implement a WIKI or a Bug Tracking Tool via an Atlassian Product

  • A client in need of custom wiki or of a bug tracking tool but lacking expert knowledge and resources to handle the technical part internally

Posted:

Download

Validation of SoftMaxPro

Client experienced troubles implementing a protocol validation in SoftMaxPro

  • Definition of the expected results and path were complex
  • Protocol needed to be reworked several times before reaching acceptance

Posted:

Download

Development and Implementation of the Robustness Index

Support required to provide success criteria in line with QbD principles

  • Implementation of a Robustness Indexaiming to translate development goals into objectively measurable success criteria to assess scientific knowledge, development and performance data to promote Quality by Design (QbD) principles in manufacturing

Posted:

Download

Dilution recipe for vaccine production

Required support to avoid batch rejection due to poor assay performance

  • A vaccine manufacturer produced a bulk drug Substance (DS)
  • Dilution with a formulation buffer is made to obtain a Drug Product ready to be filled in syringes
  • However, the titration of biologic material is subject to large uncertainty due to poor assay performance, leading to frequent and costly batch rejection

Posted:

Download

Implementing parallelism tests in JMP

Client was in urgent need for a more cost-effective solution

  • According to (statistical software) USP standards, parallelism between a pair of dose–response functions need to be tested prior to validating a potency bioassay
  • Developing acceptance criteria for one specific assay requires measuring the reference product numerous times
  • These cost a tremendous amount of time and money

Posted:

Download

Continuous Manufacturing: Development, Optimization and Validation

Client lacks strategy for Continuous Manufacturing within QbD principles

  • Client lacks experimental strategy to develop, optimize and validate a new continuous Manufacturing (CM) process in Quality by Design (QbD) framework

Posted:

Download

Biosimilarity assessment on multiple CQAs

Required multiple CQAs assessment in EU and US

  • How to deal with multiple Critical Quality Attributes (CQAs) in the assessment of a new biosimilar in compliance with EU and US regulations?

Posted:

Download

Bayesian modelling and prediction of patient recruitment

Required support for recruitment of patients for clinical trials

  • In many clinical trials, the amount of time needed to recruit the targeted number of patients is underestimated
  • Failure to recruit enough patients in the planned time frame causes delays, additional costs, etc
  • Consequently, estimating the recruitment duration is of crucial importance for the proper conduct of the trial

Posted:

Download

Automatic detection of disease events based on accelerometer data

Manual process for recording data was unreliable and expensive

  • The client installed accelerometers on mice to record disease events
  • The system detected c.100 false positives for each real event
  • Results needed to be reviewed and corrected manually by experts
  • Data accuracy critical as data set was aimed to be used in pre-clinical trials to compare different treatments

Posted:

Download

Analytical Method Comparisons

Client needed to demonstrate interchangeability of technology

  • Client needed to change from a costly and low through-put analytical technology, to an easier, faster high through-put assay

Posted:

Download

Acceptance criteria for Bioassay validation

Client was in urgent need for a more cost-effective solution for Bioassay validation

  • According to USP standards, parallelism between a pair of dose-response function needs to be tested prior to validating a potency bioassay

Posted:

Download

PharmaLex successfully changes legal status of product from POM to P

PharmaLex successfully changes the legal status of the product from POM to P

  • PharmaLex leveraged their regulatory expertise on the switching requirements and process, and their working relationship with the regulatory authorities to successfully change a product from prescription only medicine (POM) to pharmacy medicine status.

Posted:

Download

PharmaLex keeps medical device CE marking on track

PharmaLex applies expert knowledge of EU medical device regulation and achieves a positive opinion from the MHRA on a Class III medical device, despite a flawed study design.

  • A US-based company developed a class III medical device with an ancillary medicinal product (according to Rule 13, Annex IX of the Medical Device Directive 93/42/EEC).  The data were positive in a multi-center, randomised, comparative clinical trial but a prospective protocol-defined primary endpoint was flawed and unfortunately this led to early termination of the study.  With the risk of needing to repeat the trial, the company required a partner with specialist knowledge of EU medical device regulations and strong Notified Body experience to avoid a significant delay and costly consequence.

Posted:

Download

PharmaLex expertise secures CE certification for medical devices ‘at risk’

PharmaLex expertise secures CE certification for medical devices ‘at risk’

  • An EU based company manufacture a large portfolio of medical devices for the UK National Health Service. During a recent Notified Body audit, the company’s Technical Files were found to be deficient, and they were issued with a major non conformity against their Clinical Evaluation Reports (CERs).
  • With multiple reports requiring update to the new MEDDEV 2.7.1/rev4, there was a real risk of losing their CE certifications and thus, the right to sell their products in the EU. This manufacturer required a consultancy specializing in medical devices, who had clinical writing expertise and strong literature retrieval skills, together with the commitment and can do attitude to meet a very tight deadline.

Posted:

Download

PharmaLex delivers huge sales upturn with regulatory strategy

PharmaLex ensures regulatory compliance for successful pharmaceutical product acquisition with sales growth of 22% in the first year

  • A pharmaceutical company had an opportunity to buy their first medicine and needed to understand their pharmaceutical regulatory compliance obligations prior to acquisition. This was a product that had been sold for a number ofyears in many countries across the world, so there was a huge amount of complex technical and scientific data. The medicine was used to treat potentially life-threatening infections and therefore played a vital role in critical care.

Posted:

Download

PharmaLex corrects serious non-compliance issue

PharmaLex corrects serious non-compliance issue and protects millions of £s of annual sales for product range

  • PharmaLex were given the responsibility of providing regulatory services to a pharmaceutical company who had acquired two licensed medicines in a range of formulations and strengths from big pharma. These originator products had EU sales in the millions and PharmaLex were engaged to provide regulatory support to all the client’s local EU affiliate offices.

Posted:

Download

PharmaLex creativity achieves increased cosmetic product sales

PharmaLex devises regulatory strategy for a cosmetic that results in increased cosmetic and medicinal product sales in the dermatology sector for leading OTC / generic company

  • A company wanted to increase public awareness of its dermatology medicine but was unable to do so because regulations did not permit promoting the product to the public.

Posted:

Download

PharmaLex obtains rapid CE marking

PharmaLex obtains rapid CE marking for a medical device that opens up a market worth $2.2 billion

  • A US-based company had developed a Class III medical device for the treatment of hepatic cancer. The device had been designed to be used with a specific medicinal product. The company wanted to sell their product in the EU and the product must therefore carry a CE mark.

Posted:

Download

PharmaLex applies EU regulatory affairs expertise

PharmaLex applies EU regulatory affairs expertise to rescue failing market application and delivers €3m revenue in first year sales

  • A pharmaceutical company had submitted a marketing application for a new product seeking approval in ten EU countries. The company required a partner with specialist EU regulatory affairs knowledge to avoid a costly failed application.

Posted:

Download

Outsourcing pharmacovigilance activities to PharmaLex

Outsourcing pharmacovigilance activities to PharmaLex ensured full compliance and a successful MHRA PV inspection

  • A small company wished to outsource all pharmacovigilance activities. They were in the process of obtaining an EU marketing authorization and license approvals in other countries around the world for their product. As an applicant and future license holder they had to fulfil significant and complex pharmacovigilance obligations.

Posted:

Download

Computer Software Validation for Multinational Pharmaceutical Company

Pharmaceutical company acquires a European company and needs to expand in European market

  • Executive management needed deployment of ERP system at the acquired European site to support the anticipated increase in business volume and complex supply chain model
  • The pharmaceutical corporation needed computer software validation to meet US and EU regulatory requirements followed at other company locations
  • Validation efforts necessitated remote support to work alongside implementation team

Posted:

Download

Outsourcing clinical trial safety activities to PharmaLex

Outsourcing clinical trial safety activities to PharmaLex assures compliance and puts project on track for fast registration

  • A US company was dissatisfied with a large global CRO’s study and drug safety management for a programme of multinational clinical trials involving a complex drug device combination therapy. These ongoing studies were pivotal to the successful registration of the treatment in the EU and US. PharmaLexwas given responsibility for all the clinical trial safety activities.

Posted:

Download

Portfolio Maintenance Outsourcing – Global RA responsibility

Outsourcing of global well established products

  • Client was a multinational Swiss-based company
  • Due to capacity constraints the company intended to transfer outsource several mature products of their Consumer Care portfolio (OTC, Food and cosmetics)
  • Within the transfer all maintenance activities including labelling support and electronic publishing should be handled

 

Posted:

Download

Portfolio Maintenance Outsourcing Local RA responsibility – EU

Client plans to outsource RA activities in EU countries for defined products

  • High workload in local affiliates for established product portfolio in the EU
  • New products registered in the countries lead to increasing workload
  • Full RA responsibility for an established product portfolio to be outsourced for 16 EU countries
  • Cover of all RA life cycle management tasks including labeling and interaction with local partners (incl. PV, medical)
  • HA interactions done directly by PharmaLex

Posted:

Download

Safety Writing Services

Client looking to outsource PV activities to focus on core business activities and compliance function

  • Need to increase the resources available for PV activities without increasing company assets
  • Interest to have support from PV experts and collaborate with a service provider focused on PV
  • Mitigate the risk of quality issues raised during inspections from health authorities

Posted:

Download

Aggregate Report Writing and RMPs

Quality issues raised during inspections related to the source data

  • Client needs to handle increased workload in Pharmacovigilance
  • Need to reorganize Pharmacovigilance activities outsourcing those that can be easily trained and transferred
  • Client looking for an external provider to focus on PV and extensive experience in safety writing

Posted:

Download

Remediation Activities and Operational Support

German affiliate of a large US company requiring maintenance support for local GDP Quality and PV Systems

  • Looking for alternatives for their current cooperation with 2 freelancers for maintenance activities (one for GDP, one for PV). Wish to have one consultant for both areas
  • Customer considered his GDP Quality and PV Systems up-to-date
  • Limited internal staff and local know-how
  • Local PV-responsible requested
  • Specified operational GDP- and PV activities requested

Posted:

Download

Business Readiness for new German Affiliate

Newly founded German affiliate needed short-termbusiness readiness

  • Globally acting company (small-medium size) founded a German affiliate due to re-organization
  • Affiliate needed business readiness on short term (termination of contracts for precious business solutions, own sales)
  • Design of a new GDP Quality System (needed to apply for and obtain WDA*)
  • Local Pharmacovigilance support and provision of the local PV-responsible
  • Lean processes (limited resources)

Posted:

Download

Pre-IND Meeting for an antibody-drug conjugate (ADC) for an advanced cancer indication

Client in need of expertise for IND development and FDA interaction for First-in-Human study

  • European SME beginning first discussions with the FDA regarding IND development and submission of an ADC product for an advanced cancer indication
  • Intent to gain agreement on completed nonclinical program to support first in-human (FIH) study

Posted:

Download

Medical Information Service for mid-sized pharma company

Mid-size pharma company with personnel shortage for Medical Information Services

  • Mid-size pharmaceutical company acquiring well-established European OTC product portfolio from global pharmaceutical company
  • Personnel shortage therefore outsourcing of Medical Information (MI) support for DE / CH / AT / PT / GR / HU / CZ / NO / SE
  • PharmaLex project lead support company’s project leads working in collaboration with internal functions and MI call center vendor on tasks related to oversight and management of MI support

Posted:

Download

Medical Information Service for large pharma company

Client was a global large pharma company
Due to personnel shortages client was in need of support for:

  • PQCs documentation and management of field sample retrieval
  • Technical and medical queries documentation in a harmonized way that allows extracting of patterns and data for quarterly / yearly reports
  • Advance knowledge in Pharmacovigilance that allows the team to recognize adverse events and medication errors quickly and efficiently

Posted:

Download

Full service Post-Marketing Pharmacovigilance and Medical Information Services for large nutritional health company

Rapid set up and go live for  PV and Med Info Services

  • Large nutritional health company with newly acquired Rx products in US and Canada required urgent full support with all PV activities, Medical Information contact center services, as well as data migration of cases from prior MAH
  • New to prescription drug market with 3-week timeline to take over PV and Call Center responsibilities
  • Need of additional support for NDA maintenance support, promotional materials development and review, and product complaint management

Posted:

Download

Parallel NDA/MAA eCTD Submission

3 dossiers  (an NDA and 2 MAA) for initial application for DP for prevention of pregnancy

  • Dossiers for EMA and FDA with differences in the requirements
  • Support for the client (one US NDA and one EU MAA) and their third-party collaboration partner (one additional EU MAA)
  • Differences in the administrative part of the dossiers and following updates of M1 and M2 documents
  • Short notice changes before the planned submission dates due to difficult alignment between affected parties

Posted:

Download

Regulatory Operations IND transition to eCTD

PharmaLex network of resources and experience utilized to guide the client to success

  • CMC subject matter expertise for gene therapy was provided to effectively map eCTD locations of legacy documents
  • Anchor eCTD submissions were established and dispatched through the FDA electronic submissions gateway to begin the eCTD submission management
  • Experienced regulatory operations managers guided the client regarding the nature of lifecycle operators and eCTD granularity
  • Technical support was provided for eCTD templates

Posted:

Download

Full service post-marketing and clinical trial PV activities for mid-sized pharma company

  • US company developing a modified release formulation for an existing active ingredient needed full support with all routine PV activities, as well as migration of the global safety database
  • Expanding to new markets and awaiting approval in EU and Canada
  • Needed support for introduction of new products into the EU as well as further expansion in the US
  • Needed local presence in the EU to liaise with their marketing partners without the need to set up their own infrastructure
  • Dynamic growth of company required flexible up- and down-scaling of resources

Posted:

Download

MA applications to EMA and FDA in parallel

  • A European pharmaceutical company has identified the need for support from a service provider due to the lack of capacities and capabilities to process both applications in parallel
  • Support for various regulatory activities in relation to the preparation, submission and coordination of both applications (EU/US)
  • Outstanding Project Management expertise required to meet requirements of large project

Posted:

Download

Dendritic cell vaccine (oncology)

  • Small biotech US company developing a dendritic cell vaccine for the treatment of the Orphan indication glioblastoma in EU
  • Timeline: long-term (8 years)
  • Support in

-Preparation and conduct of the Scientific Advices (SA)

-Medical and technical Writing

-Clinical trial Phase III

-Adaptive pathway

-Early access medicines scheme (UK)

-Hospital exemption (DE)

-Pediatric Investigational Plan (PIP)

-Pharmacovigilance: DSUR and PSUR

Posted:

Download

Regulatory CMC Compliance reduced risk

  • Identified deficiencies in Change Control procedures and GMP manufacturing documentation
  • Uncertainty in verifying the current registered information held with Health Authorities
  • Lack of Regulatory Information Management (RIM) systems and therefore lack of oversight of product information for key stakeholders

Posted:

Download

Definition of batches internal release limits based on stability results

A client faces multiple batch rejection due to outdated Internal Release Limits (IRLs) but he has 100+ products (500+ attributes) to analyze and follow up on a regular basis

Posted:

Download

Pre-IND Meeting

  • Company beginning first discussions with the FDA regarding IND development and submission of intra-cerebral gene therapy product
  • Intent to gain agreement on completed nonclinical program to support first in human study
  • Intent to gain agreement on the use of historical controls to support clinical development in rare disease space

Posted:

Download

Type C Meeting

US Company developing a patient-reported outcome (PRO) as the primary endpoint for the Phase 3 program

  • Under guidance from FDA, the company performed multiple Phase 1 and 2 studies to support validation of PRO efficacy measuring tool
  • Company intent to gain agreement on validation of PRO for use in Phase 3 studies to support small molecule development for celiac disease

Posted:

Download

End of Phase-2 meeting

European client entering a pivotal program in a competitive market

  • EU based company developing a gastrointestinal product in a competitive and controversial market (opioids)
  • The company intends to pursue adaptive Phase 2/3 clinical program to expedite late-stage development
  • Company intent to gain agreement from FDA on completion of non-clinical and CMC (quality) program to support marketing approval

Posted:

Download

RIM-DMS Data Clean-up

300 GB of unstructured and partially structured documents, and files during marketing authorization transfer

  • The client acquired a large portfolio of marketing authorizations
  • Data transfer was documented, but documents and files were highly unstructured
  • Fully structured and valid data, documents and files to be imported into Veeva Vault RIM
  • Timelines for the project defined by marketing authorization transfer submissions and any regulatory maintenance activities

Posted:

Download

Veeva Vault RIM Implementation

Limited internal resources and minimal experience with RIM implementation projects

  • US-headquartered biopharmaceutical company with European affiliate
  • First NDA approved; further, NDAs planned
  • Fast-growing company with increasing Regulatory needs
  • Limited resources for project management and operational work during configuration and implement phase
  • Minimal experience with RIM implementation projects and no experience with Veeva Vault

Posted:

Download

Consultancy and eCTD submission support for master files

Manufacturer with limited eCTD knowledge and several Holder’s sites in the EU, US and China

  • Client needs to switch Master Files (MF) to eCTD format in EU, non-EU and US (later also APAC, CA)
  • Pressure from their clients (MAHs) to use eCTD
  • PharmaLex supported with:
    • Knowledge transfer, Project planning + management
    • Gap analysis and roadmap for transition
    • Full Regulatory Operations services during transition and on-going maintenance of eCTD-MFs (eCTD-readiness, compile, publish, submit)
    • Consultancy on CMC and (pre-)publishing topics and tools

Posted:

Download

Consultancy and support for IDMP implementation

  • Medium-sized pharmaceutical company in the EU
  • Client intends to prepare for upcoming IDMP implementation in Europe
  • Focus on compliance and optimal utilization of related information within the company
  • PharmaLex supported with:
    • Awareness meetings
    • Gap analysis
    • Implementation proposal covering systems, processes and data

 

Posted:

Download

Strategic outsourcing of mature product portfolio

Global innovator company.

  • Wanted to outsource parts of their mature product portfolio.
  • >60 products in different therapeutic areas
  • 430 MAs in Europe, 1,900 MAs internationally (incl. CN, AUS, CAN).
  • Scope of PharmaLex support:
    • Full regulatory product responsibility
    • GRA CMC Manager
    • All publishing and submission activities
    • Piloting of PV and Medical Affairs interface.

 

Posted:

Download

Portfolio maintenance outsourcing in highly volatile environment

Large global portfolio to be managed while client organization underwent drastic transformations

  • Portfolio of 35 products in scope.
  • Client went through several significant changes in internal organization in a short timeframe.
  • Multi-supplier situation.
  • Major remediation needs regarding change control and labeling.

 

Posted:

Download

Global CMC responsibility during portfolio integration

Tight contractual agreed timeframe and multiple data migrations and process adaptations

  • Portfolio acquired by client for which CMC maintenance already handled by PharmaLex >8 years before acquisition.
  • PharmaLex with same functional role in new company but different scope of work.
  • Compliance with changing client processes due to data migration.
  • Portfolio with > 80 INNs (chemicals, herbals, biologics) authorized worldwide.

Posted:

Download

End-2-end portfolio maintenance (outsourcing) program

Large unstructured source repository and limited timeframe

  • Diverse stakeholders within M&A activity.
  • Short preparation timelines.
  • Regulatory activities across the world (EU, CIS, APAC, MENA, Africa, LATAM).
  • Part integration into client Quality systems.

 

Posted:

Download

Post–M&A PharmaLex program governance

Start-up Pharma company with no REG, PV, Quality infrastructure with urgent need for Programme Governance to be established

  • Major pharma portfolio asset purchase (approx. 20 products and 450 MAs, across 47 markets) .
  • No ability to support program governance of multi-functional Regulatory Affairs (RA), Pharmacovigilance (PV) and Quality Management (QM) operational activities
  • Required urgent support to provide operational activities and oversight, with the ability to establish an appropriate program governance model as required for a Pharmaceutical company.

 

Posted:

Download

Post–M&A pharma infrastructure development

Start-up Pharma company with no REG, PV, Quality systems infrastructure, processes and limited personnel

  • Client start-up with major pharma portfolio asset purchase (approx. 20 products and 450 MAs, across 47 markets).
  • Client has no Regulatory Affairs (RA), Pharmacovigilance (PV) and Quality Management (QM) capacities in-house (neither globally nor locally) to take care of the acquired portfolio and no established systems, tools or processes.
  • Needed support to handle all MAH transfers and subsequent maintenance activities for RA, PV and QM on global and local level.

 

Posted:

Download

M&A early strategy

Need for significant M&A strategy experience and expertise to support development of divestment framework

  • Needed expert support for the negotiation phase of a significant divestment of a business unit, during negotiation and strategy development phases.
  • Wanted external support to contribute to separation agreement, transitional service agreements (TSAs) and marketing authorization transfer (MAT) planning / implementation phases
  • Challenge to simplify the complexity of MATs to a simple model for ease of communication.

Posted:

Download

Lifecycle management for drug products

Reluctance to compute tolerance intervals

  • Needed support with the preparation of Module 3 and corresponding Module 2.3 documents for drug substances and drug products:
    • To reflect the current status of manufacturing process and state of the scientific art analytical procedures
    • To close gaps and achieve GMP compliance of regulatory documentation.
  • Required on-going lifecycle management for all drug product licences needed.

Posted:

Download

Regulatory CMC compliance reduced workload by 20-25%

High additional workload due to expansion in product portfolio

  • More than 150 different formulations, resulting in more than 1200 national registration documentations worldwide.

 

Posted:

Download

Full PV service outsourcing

Lack of capability of handling unpredictable and fluctuating amount of cases

  • Client required outsourced PV service.
  • QPPV, database set-up and maintenance case management (clinical and post-marketing).
  • Case workflow set-up from initial receipt to reporting.
  • Listings and query support from database.
  • Reporting compliance responsibility.
  • PSMF maintenance.

Posted:

Download

Flexible eCTD publishing support

Global innovator company looking for flexible support and ability to meet tight deadlines

  • Global innovator company and European generics arm requiring UK local affiliate support.
  • Covering MAAs and post-approval submissions.
  • More than 250 MAs
  • Typically 25 – 30 eCTD sequences required per week across the portfolio.

Posted:

Download

eCTD submissions for global DMF portfolio

Client was lacking internal expertise during workload peaks

  • Big multi-national chemical company.
  • Client intended to switch all existing Drug Master Files (DMF – active substances as well as excipients) into eCTD format.
  • Portfolio also included Veterinary Master Files, which require a specific electronic submission format.

Posted:

Download

Regulatory publishing support on request

Client lacking resources for EU publishing activities

  • Global generic company needed support for EU publishing activities for parts of its product portfolio.
  • All EU eSubmission activities (eCTD, NeeS) were transferred to PharmaLex.
  • Scope of PharmaLex responsibilities:
    • Direct correspondence and interactions with Regulatory Affairs functions.
    • Collection of related documentation.
    • All dossier as well as submission activities.

Posted:

Download

Local lifecycle Regulatory Affairs management

Local affiliates require support for mature product portfolio in DE / FR / IT

Global life science company.

  • Responsible for product portfolio needed.
    • Handling of local tasks and procedure management handled by one person on client site.
    • Contact person for HA requests needed.
    • Ability to correspond fluently in local language is crucial.

Posted:

Download

Due diligence for medicinal product documentation

Evaluation of drug product documentation under time pressure

  • Medium-sized EU-based pharmaceutical company.
  • The client intended to acquire the marketing authorizations for three strengths of an oral anti-diabetic medicinal product intended for use in patients with type II diabetes.
  • Client was in the need of due diligence to review the dossier and assess the quality of a planned acquisition by the company before imminent expiry (Sunset Clause).

Posted:

Download

Multi-country Phase III clinical trial support

Market specific CTA applications for a multi-country EU Phase III clinical trial

  • Assistance required to review core documentation.
  • Authoring of local documentation for country specific submissions.
  • Assistance with competent authority and ethics committee communication.
  • Support with handling of substantial amendments to competent authorities and ethics committees, as required.

Posted:

Download

US-UK Phase II clinical trial support

Support for timely approval of a Phase II clinical trial in the US and UK

  • Required assistance in IND authoring, eCTD publishing and FDA Agent activities for submission to FDA.
  • Alongside support in authoring of IMPD and local documentation required for submission to MHRA.

Posted:

Download

Preparation, submission and coordination of a CP for PUMA

Needed expertise for regulatory strategy and support for execution for CP and PUMA formulation

  • A small European pharmaceutical company has identified the need for support due to lack of capacity and capability to process a centralized procedure for a PUMA formulation.
  • PharmaLex offered support for various regulatory activities in relation to the preparation, submission and coordination of the centralized procedure.
  • Project management.
  • Definition and tracking of KPIs and budget.

Posted:

Download

Strategy and delivery of global biosimilar development program

Needed expertise for biosimilar regulatory strategy and support with execution

Posted:

Download

ERA for an active substance in antiseptic lozenges

Environmental Risk Assessment accepted by environmental agency; costs manageable

  • Client developed antiseptic lozenges for the treatment of sore throat.
  • Support was needed for compilation of an ERA.
  • Scope of required studies was unclear.
  • High costs for anticipated experimental study set.
  • Scientific Advice meeting at environmental agency required.
  • Contract research laboratories required for experimental work.

Posted:

Download

Quality Management System

Client was a large Canadian pharmaceutical company requiring an experienced provider to develop the Quality Management System for their supply chain and distribution office.

Posted:

Download